Over the last decade, 29 patients with agnogenic myeloid metaplasia had splenectomies. Indications for splenectomy included hemolytic anemia, thrombocytopenia, mechanical splenomegaly, and portal hypertension. The 13 women tended to be younger when splenectomized, had a longer duration of illness before splenectomy, and had the procedure for pressure symptoms, thrombocytopenia, or portal hypertension.Fifty percent of the men had serious postoperative complications, compared with only 23% of the women; 50% of the women survived at least five years after the procedure, whereas only two men are living two years after the procedure, and 14 have died within an average of two years after splenectomy. AGNOGENIC